By: Dr. Shane Kurth, D.C., BCN
Co-Owner, Radiant Results
Updated September 2026
This article explains the biological mechanisms behind menopause-related skin changes — specifically why collagen loss accelerates after estrogen declines — and reviews the current evidence for skin care interventions, including hormone therapy and non-hormonal options such as red light therapy. It is intended as a clinical education resource for women navigating perimenopause, menopause, or post-menopause. It does not replace a consultation with a qualified healthcare provider for hormonal or systemic concerns.
Medical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. Menopause and perimenopause involve complex hormonal changes that may require evaluation by a qualified physician, OB/GYN, or functional medicine provider. Radiant Results offers non-hormonal, medical-grade red light therapy — not hormone replacement therapy. Please consult a licensed healthcare provider before making changes to any treatment plan.
Menopause Skin Care in Uptown Charlotte, NC
Menopause causes the skin to lose collagen at an accelerated rate. Declining estrogen impairs fibroblast activity — the cells responsible for building collagen — and studies suggest women may lose up to approximately 30% of skin collagen in the first five years after menopause. Non-hormonal options, including medical-grade red light therapy (photobiomodulation), can directly support collagen production without altering hormone levels.
Key Takeaways
- Estrogen acts directly on fibroblasts — the skin’s collagen-producing cells. When estrogen declines during menopause, collagen production drops and enzymatic breakdown accelerates simultaneously, compounding the structural loss.
- Research consolidated by Viscomi et al. (2025) suggests up to approximately 30% of skin collagen may be lost in the first five years after menopause, followed by roughly 2% additional loss per year — distinctly steeper than the 1–1.5% annual loss associated with ordinary aging.
- Perimenopause, which typically begins in the mid-40s, is the clinically preferable window to start proactive skin care. The collagen decline begins before periods stop, and it is easier to slow structural change than to reverse it.
- Red light therapy (photobiomodulation) is a non-hormonal, non-prescription option with clinical evidence for collagen density improvement. It does not treat vasomotor symptoms such as hot flashes or night sweats and is not a substitute for physician-supervised evaluation for HRT.
- Evidence strength for red light therapy on skin: moderate-to-strong for collagen density and texture outcomes, based on controlled trials including Wunsch & Matuschka (2014, Photomedicine and Laser Surgery) and the review by Avci et al. (2013, Seminars in Cutaneous Medicine and Surgery).
Why Menopause Changes Your Skin — The Estrogen-Collagen Connection
Estrogen is not a hormone that operates only in the reproductive system. It has direct receptor sites in the skin — specifically on fibroblasts, the mesenchymal cells responsible for synthesizing both collagen and elastin. When estrogen levels decline during the menopause transition, those receptor-mediated signals weaken. The consequences at the tissue level are measurable. As Viscomi, Muniz, and Sattler document in their 2025 narrative review in the Journal of Cosmetic Dermatology, estrogen decline during menopause contributes directly to decreased collagen production, reduced skin elasticity, and moisture loss — changes driven by biology, not lifestyle.
What makes menopause-driven skin change distinctly different from ordinary aging is a dual-failure mechanism. Estrogen loss simultaneously impairs fibroblast signaling — slowing new collagen synthesis — and fails to suppress matrix metalloproteinases (MMPs), the enzymes that break down existing collagen. Production drops while breakdown continues unchecked. Avci et al. (2013) describe this fibroblast-collagen relationship as central to understanding why photobiomodulation has dermatologic relevance. The same cellular pathway that estrogen modulates is one that light therapy can independently stimulate: Hamblin’s peer-reviewed review of photobiomodulation mechanisms documents how cytochrome c oxidase activation in the mitochondria drives this effect.
The clinical result is a cluster of changes appearing in a relatively short window: skin thinning, reduced firmness, increased dryness, fine lines in previously unaffected areas, and a change in overall texture. These are not signs of neglect. They are a measurable biological response to a hormonal shift. Understanding the mechanism is the starting point for choosing an intervention that addresses the underlying biology rather than surface appearance alone. For a broader look at how photobiomodulation supports collagen production in aging skin, our skin rejuvenation service covers the full evidence base.
How Skin Shifts from Perimenopause Through Post-Menopause
Menopause-related skin change unfolds across three distinct phases — with different mechanisms dominant at each — and that matters because it changes what proactive care looks like.
Stage 1 — Perimenopause (typically mid-40s, lasting up to a decade): Estrogen levels during perimenopause fluctuate rather than decline in a straight line, which means skin changes at this stage are often subtle and inconsistent. Women may notice occasional dryness, a slight loss of plumpness, or unexpected hormonal breakouts along the jawline. That jawline pattern is explained by the fact that sebaceous glands, like fibroblasts, carry estrogen receptors. Viscomi et al. (2025) identify perimenopausal skin quality changes as part of the same declining-estrogen continuum, beginning before menopause is formally established. This is the intervention window providers rarely discuss — and clinically it is the most important one.
Stage 2 — Menopause (defined as 12 consecutive months without a period): This is when the steepest estrogen decline occurs and the most noticeable skin changes cluster. Loss of skin thickness, more pronounced fine lines, increased sensitivity, dullness, and accelerated change in the jawline and neck — where collagen scaffolding is naturally thinner — tend to converge in this phase.
Stage 3 — Post-menopause: Estrogen stabilizes at a lower baseline, and the acute rate of collagen loss slows to approximately 2% per year after the initial steep decline. Without active support, structural changes accumulate. Skin becomes more vulnerable to UV damage, environmental stress, and slower wound healing, as the fibroblast response underlying healing also depends on hormonal signaling that has diminished.
| Skin Change | When It Typically Appears | Primary Mechanism |
|---|---|---|
| Loss of firmness / early sagging | Late perimenopause → early menopause | Reduced fibroblast activity → collagen scaffold weakening |
| Dryness and thin skin texture | Perimenopause → menopause | Loss of glycosaminoglycans (hydration-retaining molecules) tied to estrogen decline |
| Fine lines in new locations | Menopause transition | Collagen loss + reduced elastin cross-linking |
| Increased sensitivity / redness | Perimenopause | Reduced skin barrier integrity; sebaceous gland changes |
| Slower wound healing / recovery | Post-menopause | Reduced vascularization; impaired fibroblast response |
The takeaway from this staging is direct: a woman in her mid-40s who notices her skin feels different is not too early to start — she is at the optimal point. Skin changes are easier to slow than to reverse.
The 30% Collagen Loss Statistic — What It Means for a Care Routine
Peer-reviewed research consolidated by Viscomi et al. (2025) suggests women may lose up to approximately 30% of their skin collagen in the first five years after menopause, with roughly 2% additional loss per year thereafter — a decline documented in both type I and type III collagen within that first five-year window. Individual variation exists, and these figures represent patterns across research populations.
The distinction from ordinary aging matters clinically. Regular aging produces approximately 1–1.5% collagen loss per year beginning in early adulthood — a gradual, predictable decline. Menopause superimposes a steeper, hormonally driven drop on top of that baseline. The change is not gradual. This acceleration is sometimes described in informal clinical shorthand as a “collagen cliff” — the reason many women describe the change as feeling sudden, even when it has been building at the cellular level for years.
Translating this to practical terms: a 30% structural reduction in dermal collagen means reduced firmness, increased wrinkling, thinning, and slower skin repair. This is not a cosmetic inconvenience. It represents a measurable change in the functional integrity of the skin — its barrier function, its healing capacity, and its resistance to environmental stress. Understanding the magnitude helps women make informed decisions about which interventions target collagen stimulation at the fibroblast level, rather than surface-level hydration or reflectance alone.
Evidence-Based Skin Care Options for Menopausal Women
A clinical resource for menopausal skin care should present the honest evidence hierarchy. Three main categories of intervention have meaningful clinical support, each with different evidence strength and different mechanisms.
Topical retinoids / vitamin A derivatives — evidence strength: strong. Multiple randomized controlled trials support topical retinoids as collagen-stimulating agents in aging skin. They work by activating nuclear receptors that upregulate collagen gene expression and suppress MMP activity. Available by prescription (tretinoin) and over the counter (retinol), these are not a Radiant Results service — but they are an honest first-line consideration that integrates well with other approaches.
Hormone replacement therapy (HRT) for skin — evidence strength: moderate. As Viscomi et al. (2025) document, HRT can enhance skin quality by promoting collagen synthesis, elasticity, and hydration through systemic estrogen receptor activation. The skin benefits of HRT are real and mechanistically coherent. However, HRT carries a full benefit-risk profile extending well beyond skin — cardiovascular considerations, cancer history, individual baseline — and is a physician-supervised decision that falls entirely outside Radiant Results’ scope. HRT is an option worth discussing with an OB/GYN or functional medicine provider; Radiant Results is not the place to make that decision.
Medical-grade red light therapy / photobiomodulation — evidence strength: moderate-to-strong for collagen density and skin texture outcomes in controlled trials; emerging for menopause-specific populations. This is the non-hormonal, non-prescription option with direct mechanistic relevance to fibroblast function. For women who prefer not to take HRT, cannot take it, or who want complementary skin support alongside HRT, our fibroblast-targeted red light skin rejuvenation addresses the same collagen pathway through an entirely different mechanism. These options are not mutually exclusive.
How Red Light Therapy Supports Collagen Production During Menopause
The mechanism begins at the cellular level. Red light at approximately 630–660nm penetrates to the dermis — roughly 8–10mm into skin tissue — which is precisely where fibroblasts reside. Near-infrared light at approximately 810–850nm penetrates to approximately 2–5cm depth, reaching deeper connective tissue layers. At the mitochondrial membrane, photons are absorbed by cytochrome c oxidase — the terminal enzyme in the electron transport chain — triggering increased ATP production. For fibroblasts, this cellular energy upregulation translates directly to increased synthesis of collagen and elastin. Avci et al. (2013), in their review of low-level light therapy in skin, identify fibroblast stimulation and collagen production as central dermatologic effects of this pathway.
The clinical evidence most directly relevant to menopausal skin comes from Wunsch and Matuschka (2014). Their controlled trial in Photomedicine and Laser Surgery (PMC3926176) evaluated red and near-infrared light treatment in 136 subjects over 30 sessions. The trial found significant improvements in skin roughness, skin complexion, and intradermal collagen density — with collagen density changes confirmed by ultrasound imaging, not self-report. Because menopausal skin loss is driven specifically by impaired fibroblast function, a therapy that directly upregulates fibroblast activity addresses the underlying biology rather than masking surface symptoms.
Evidence strength should be stated accurately: moderate-to-strong for collagen density and texture outcomes based on controlled trial data; emerging for a menopause-specific population, where fewer targeted RCTs exist. The mechanism is well-established; the population-specific evidence is growing.
At Radiant Results, full-body red light therapy sessions are delivered using the Dahlia Full Body Medical Grade Light Therapy Bed, which emits both red (~630–660nm) and near-infrared (~810–850nm) wavelengths simultaneously across the full body in 15-minute sessions. The Dahlia includes a facial protection pad as a design feature during full-body treatment.
| Session Window | What the Evidence Suggests |
|---|---|
| Weeks 1–4 | No visible structural change expected; cellular ATP and fibroblast activity begins upregulating. Some clients report improved skin texture or brightness at this early stage — this reflects client-reported experience, not a documented clinical outcome for this window. |
| Weeks 4–8 | Early improvements in skin texture and tone may become noticeable. Wunsch & Matuschka (2014) found measurable skin roughness changes within the first month of consistent treatment. |
| Weeks 8–16 | Intradermal collagen density changes measurable by ultrasound in the Wunsch & Matuschka protocol appeared in the 30-session range (approximately 15 weeks). This is the window where most structural improvements consolidate. |
| Beyond 16 weeks | Continued maintenance sessions support ongoing collagen renewal. Menopausal skin benefits from a sustained protocol rather than a single-course treatment. |
Results vary by individual baseline, existing collagen loss, and consistency of sessions. These timelines reflect what the cited clinical evidence suggests — not a guaranteed outcome.
Choosing a Menopause Skin Care Provider in Uptown Charlotte
Women who have researched menopausal skin care thoroughly tend to ask better questions than most provider intake processes are designed to answer. The following criteria apply to evaluating any menopause-focused skin care provider, including Radiant Results.
Named clinical oversight. Does the practice have a named clinician — a physician, chiropractor, or board-certified practitioner — who reviews treatment protocols and is accessible for clinical questions? A named author on a web page is a starting signal, not a guarantee, but its absence is informative.
Medical-grade equipment with verified wavelength delivery. Consumer LED panels and clinical photobiomodulation devices are not equivalent. A provider should be able to specify the wavelengths delivered, the device classification, and why the equipment meets a medical-grade standard — not simply describe it as “professional.”
Honest intake and contraindication screening. Before beginning photobiomodulation, a responsible provider screens for photosensitizing medications, active skin conditions at the treatment site, implanted electronic devices (including pacemakers), pregnancy, and active malignancy. If a provider skips this step, that is a clinical red flag.
Transparent session protocols. Session length, recommended frequency, and realistic timelines should be communicated before a client commits.
Appropriate referral posture. A provider offering non-hormonal skin support should acknowledge clearly when a client should also see an OB/GYN or functional medicine provider for hormonal evaluation. Red light therapy is not a complete menopause management plan.
Radiant Results’ Uptown Charlotte location meets each of these criteria: clinical oversight by Dr. Shane Kurth (D.C., BCN), medical-grade Dahlia bed with verified wavelength delivery, 15-minute full-body sessions, and a clinical commitment to referring clients for hormonal evaluation when the presentation warrants it.
Honest Limitations — What Red Light Therapy Does and Doesn’t Do for Menopausal Skin
What red light therapy does not do for menopausal skin:
It does not alter hormone levels or replace the effects of estrogen on the body. There is no mechanism by which photobiomodulation affects the endocrine system — estrogen production, receptor sensitivity, or hormonal signaling systemically. Women who need hormonal support need to see a physician.
It does not treat vasomotor symptoms. Hot flashes, night sweats, and sleep disruption are outside the scope of evidence for red light therapy. Any provider or resource suggesting otherwise is overstating the evidence.
It does not provide the same collagen-protective effect as HRT. HRT’s skin benefits operate systemically through estrogen receptor activation across the entire body. Red light therapy works locally — it upregulates fibroblast activity in the tissue exposed to light. Both mechanisms are real; they are not equivalent.
It does not replace physician evaluation for systemic menopause management. Cardiovascular health, bone density, cognitive changes, and quality of life outcomes associated with menopause require clinical oversight that falls entirely outside what any light therapy practice can or should provide.
Contraindication screening: Radiant Results’ clinical intake process screens for photosensitizing medications, active skin conditions at the treatment site, implanted electronic devices including pacemakers, and pregnancy. Clients with active malignancy or a personal history of certain cancers should consult their oncologist before beginning photobiomodulation. Individuals with autoimmune skin conditions — including lupus — should discuss treatment with their physician before proceeding. The FDA’s overview of light therapy devices provides context on how these devices are classified in the United States.
What it does well: For women who cannot take HRT, prefer not to, or who want complementary collagen-supporting care alongside physician-supervised hormonal therapy, photobiomodulation offers the most clinically evidenced non-hormonal collagen-stimulation option currently available without a prescription. The mechanism is sound, the controlled trial evidence is meaningful, and the risk profile — for appropriately screened clients — is favorable.
Getting Started — Menopause Skin Care at Radiant Results, Uptown Charlotte
Women navigating the perimenopause or menopause transition who want evidence-based, non-hormonal collagen support have a local option with clinical oversight. Radiant Results’ Uptown Charlotte location offers medical-grade full-body red light therapy sessions using the Dahlia bed — 15 minutes per session, delivering both red (~630–660nm) and near-infrared (~810–850nm) wavelengths — under the clinical oversight of Dr. Shane Kurth, D.C., BCN.
The $79 New Patient Special includes your first full-body red light therapy session and an initial clinical intake.
Radiant Results — Uptown Charlotte
535 Yellowstone Drive · Charlotte, NC 28208 · (704) 235-1375If you are ready to start, claim the $79 New Patient Special and we will take it from there.
Frequently Asked Questions
What does menopause do to your skin?
Declining estrogen directly impairs fibroblasts — the skin’s collagen-producing cells — while simultaneously failing to suppress the enzymes that break collagen down. The result is accelerated collagen and elastin loss, reduced moisture retention, and a thinner, less resilient skin barrier. Viscomi, Muniz, and Sattler (2025, Journal of Cosmetic Dermatology) document this estrogen-to-fibroblast-to-collagen chain as the central mechanism behind menopause-related skin quality changes.
How much collagen do you lose during menopause?
Research consolidated by Viscomi et al. (2025) suggests women may lose up to approximately 30% of their skin collagen in the first five years after menopause, followed by roughly 2% additional loss per year. This is substantially steeper than the 1–1.5% annual loss associated with ordinary aging. Individual variation exists, and these figures represent patterns across research populations.
Can red light therapy help menopausal skin?
Yes, for collagen density and skin texture, with moderate-to-strong controlled-trial evidence. Red light at 630–660nm reaches the dermis where fibroblasts reside and stimulates collagen synthesis through cytochrome c oxidase activation. Wunsch and Matuschka’s 2014 controlled trial documented ultrasound-confirmed increases in intradermal collagen density. Evidence specific to menopausal populations is still emerging, but the mechanism directly addresses the fibroblast impairment that drives menopausal skin change.
Is red light therapy a substitute for hormone replacement therapy?
No. Red light therapy does not alter hormone levels and does not treat systemic menopause symptoms such as hot flashes, night sweats, or bone density changes. It works locally to support collagen production in the tissue exposed to light. HRT works systemically through estrogen receptor activation. For skin specifically, red light therapy is a non-hormonal option for women who cannot or prefer not to take HRT — or a complement to it — but it is not a replacement for physician-supervised menopause care.
When should I start menopause skin care — perimenopause or after?
Perimenopause, typically beginning in the mid-40s, is the clinically preferable window. Collagen decline begins before periods stop, while estrogen is fluctuating rather than fully depleted. Starting proactive, collagen-supporting care during this window is more effective than waiting, because it is easier to slow structural change than to reverse it once significant loss has accumulated.
Where can I get medical-grade red light therapy for menopausal skin in Uptown Charlotte, and do I need a prescription?
Radiant Results’ Uptown Charlotte location offers medical-grade full-body red light therapy using the Dahlia bed, under the clinical oversight of Dr. Shane Kurth, D.C., BCN. No prescription is required — photobiomodulation is a non-hormonal, non-prescription option. The $79 New Patient Special includes a first full-body session and an initial clinical intake, which screens for contraindications before treatment begins.
Sources
- Viscomi B, Muniz M, Sattler S. “Managing Menopausal Skin Changes: A Narrative Review of Skin Quality Changes, Their Aesthetic Impact, and the Actual Role of Hormone Replacement Therapy in Improvement.” Journal of Cosmetic Dermatology. 2025;24(Suppl 4):e70393. PMID: 40847905. PMC12374573.
- Avci P, Gupta A, Sadasivam M, et al. “Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring.” Seminars in Cutaneous Medicine and Surgery. 2013;32(1):41–52. PMC4126803. (Cited for skin fibroblast/collagen relevance.)
- Hamblin MR. “Mechanisms and Applications of the Anti-Inflammatory Effects of Photobiomodulation.” AIMS Biophysics. 2017. PMC5523874. (Cited for cytochrome c oxidase mechanism.)
- Wunsch A, Matuschka K. “A Controlled Trial to Determine the Efficacy of Red and Near-Infrared Light Treatment in Patient Satisfaction, Reduction of Fine Lines, Wrinkles, Skin Roughness, and Intradermal Collagen Density Increase.” Photomedicine and Laser Surgery. 2014;32(2):93–100. PMID: 24286286. PMC3926176. DOI: 10.1089/pho.2013.3616.
- FDA — Light Therapy Devices. https://www.fda.gov/medical-devices/home-use-devices/light-therapy-devices
